The role of population PK-PD modelling in paediatric clinical research

European Journal of Clinical Pharmacology

Volumn 67, Issue SUPPL. 1, 2011, Pages

  De Cock, Roosmarijn F W ^a   Piana, Chiara ^a   Krekels, Elke H J ^a,b   Danhof, Meindert ^a   Allegaert, Karel ^d   Knibbe, Catherijne A J ^a,b,c  

^a LEIDEN UNIVERSITY   (Netherlands)

^b SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^c ST ANTONIUS HOSPITAL   (Netherlands)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Paediatric population; Pharmacodynamics; Pharmacokinetics; Population modelling; Validation

Indexed keywords

AGE; ANALYSIS OF COVARIANCE; ANALYTICAL ERROR; BODY WEIGHT; BOOTSTRAPPING; CLINICAL RESEARCH; DRUG RESEARCH; HUMAN; MATHEMATICAL MODEL; NONLINEAR SYSTEM; NORMAL DISTRIBUTION; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; REVIEW; STRUCTURAL EQUATION MODELING; STUDY DESIGN; VALIDATION STUDY;

BIOMEDICAL RESEARCH; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MODELS, BIOLOGICAL; NONLINEAR DYNAMICS; PEDIATRICS; PHARMACOKINETICS;

EID: 79955596580     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-009-0782-9     Document Type: Review

References (74)

1. Ernest TB, Elder DP, Martini LG et al (2007) Developing paediatric medicines: identifying the needs and recognizing the challenges. J Pharm Pharmacol 59(8):1043-1055 (Pubitemid 47265351)
2. Jong GW, Vulto AG, de Hoog M et al (2001) A survey of the use of off-label and unlicensed drugs in a Dutch children's hospital. Pediatrics 108(5):1089-1093 (Pubitemid 33021180)
3. Conroy S, Choonara I, Impicciatore P et al (2000) Survey of unlicensed and off label drug use in paediatric wards in European countries. European Network for Drug Investigation in Children. BMJ 320(7227):79-82 (Pubitemid 30173044)
4. Tod M, Jullien V, Pons G (2008) Facilitation of drug evaluation in children by population methods and modelling. Clin Pharmacokinet 47(4):231-243 (Pubitemid 351367434)
5. Bray RJ (1998) Propofol infusion syndrome in children. Paediatr Anaesth 8(6):491-499
6. Parke TJ, Stevens JE, Rice AS et al (1992) Metabolic acidosis and fatal myocardial failure after propofol infusion in children: five case reports. BMJ 305(6854):613-616
7. Sutherland JM (1959) Fatal cardiovascular collapse of infants receiving large amounts of chloramphenicol. AMA J Dis Child 97 (6):761-767
8. McIntyre J, Choonara I (2004) Drug toxicity in the neonate. Biol Neonate 86(4):218-221 (Pubitemid 39482588)
9. Nederland Kenniscentrum Farmacotherapie bij Kinderen. http://www.kinderformularium.nl. Accessed on 29 June 2009
10. European Medicines Agency (EMEA): Medicines for children. http://www.emea.europa.eu/htms/human/paediatrics/introduction.htm. Accessed on 17 June 2009
11. Dunne J (2007) The European Regulation on medicines for paediatric use. Paediatr Respir Rev 8(2):177-183
12. Consultant PR (2006) EU paediatric regulation for testing medicines in children. http://www.child-medicines-research-info. com/paediatric-research- consultancy/eu-paediatric-regulation.asp. Accessed on 23 June 2009
13. Saint Raymond A, Brasseur D (2005) Development of medicines for children in Europe: ethical implications. Paediatr Respir Rev 6 (1):45-51 (Pubitemid 40220869)
14. Kearns GL, Abdel-Rahman SM, Alander SW et al (2003) Developmental pharmacology-drug disposition, action, and therapy in infants and children. N Engl J Med 349(12):1157-1167 (Pubitemid 37122329)
15. Grand RJ, Watkins JB, Torti FM (1976) Development of the human gastrointestinal tract. A review. Gastroenterology 70(5 PT.1):790-810
16. Anderson BJ, van Lingen RA, Hansen TG et al (2002) Acetaminophen developmental pharmacokinetics in premature neonates and infants: a pooled population analysis. Anesthesiology 96(6):1336-1345 (Pubitemid 34587201)
17. Hines RN, McCarver DG (2002) The ontogeny of human drug-metabolizing enzymes: phase I oxidative enzymes. J Pharmacol Exp Ther 300(2):355-360 (Pubitemid 34106223)
18. De Wildt SN, Kearns GL, Leeder JS et al (1999) Glucuronidation in humans. Pharmacogenetic and developmental aspects. Clin Pharmacokinet 36(6):439-452
19. Leeder JS (2004) Translating pharmacogenetics and pharmacogenomics into drug development for clinical pediatrics and beyond. Drug Discov Today 9(13):567-573
20. Krekels EH, van den Anker JN, Baiardi P et al (2007) Pharmacogenetics and paediatric drug development: issues and consequences to labelling and dosing recommendations. Expert Opin Pharmacother 8(12):1787-1799 (Pubitemid 47316143)
21. Rhodin MM, Anderson BJ, Peters AM et al (2009) Human renal function maturation: a quantitative description using weight and postmenstrual age. Pediatr Nephrol 24(1):67-76
22. Bartelink IH, Rademaker CM, Schobben AF et al (2006) Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations. Clin Pharmacokinet 45(11):1077-1097 (Pubitemid 44631388)
23. Knibbe CA, Koster VS, Deneer VH et al (1998) Determination of propofol in low-volume samples by high-performance liquid chromatography with fluorescence detection. J Chromatogr B Biomed Sci Appl 706(2):305-310 (Pubitemid 28130317)
24. RauhM, Stachel D, KuhlenMet al (2006) Quantification of busulfan in saliva and plasma in haematopoietic stem cell transplantation in children: validation of liquid chromatography tandem mass spectrometry method. Clin Pharmacokinet 45(3):305-316
25. Edelbroek PM, van der Heijden J, Stolk LM (2009) Dried blood spot methods in therapeutic drug monitoring: methods, assays, and pitfalls. Ther Drug Monit 31(3):327-336
26. Jabeen R, Payne D, Wiktorowicz J et al (2006) Capillary electrophoresis and the clinical laboratory. Electrophoresis 27 (12):2413-2438 (Pubitemid 43985958)
27. Fisher DM, O'Keeffe C, Stanski DR et al (1982) Pharmacokinetics and pharmacodynamics of d-tubocurarine in infants, children, and adults. Anesthesiology 57(3):203-208 (Pubitemid 12057041)
28. LeDez KM, Lerman J (1987) The minimum alveolar concentration (MAC) of isoflurane in preterm neonates. Anesthesiology 67 (3):301-307 (Pubitemid 18077407)
29. Blusse van Oud-Alblas HJ, Peeters M, Brill MJE, Knibbe CAJ, Klein J, Tibboel D, Weber F (2009) The pharmacodynamics of isoflurane in children using Bispectral index and composite auditory evoked potentials. www.page-meeting.org/ ?abstract=1576
30. Stephenson T (2005) How children's responses to drugs differ from adults. Br J Clin Pharmacol 59(6):670-673
31. Van Dijk M, de Boer JB, Koot HM et al (2000) The reliability and validity of the COMFORT scale as a postoperative pain instrument in 0 to 3-year-old infants. Pain 84(2-3):367-377 (Pubitemid 30074240)
32. Peeters MY, Prins SA, Knibbe CA et al (2006) Pharmacokinetics and pharmacodynamics of midazolam and metabolites in non-ventilated infants after craniofacial surgery. Anesthesiology 105 (6):1135-1146 (Pubitemid 44808577)
33. Peeters MY, Prins SA, Knibbe CA et al (2006) Propofol pharmacokinetics and pharmacodynamics for depth of sedation in nonventilated infants after major craniofacial surgery. Anesthesiology 104(3):466-474
34. Van Dijk M, Peters JW, van Deventer P et al (2005) The COMFORT Behavior Scale: a tool for assessing pain and sedation in infants. Am J Nurs 105(1):33-36
35. Jonsson EN, Karlsson MO (1999) Xpose-an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 58(1):51-64 (Pubitemid 29049052)
36. FDA C (1999) Guidance for industry. Population pharmacokinetics. http://www.fda.gov/downloads/Drugs/GuidanceCompliance RegulatoryInformation/ Guidances/ucm072137.pdf
37. FDA C (1998) Guidance for industry. General considerations for pediatric pharmacokinetic studies for drugs and biological products (Draft Guidance). http://www.fda.gov/downloads/Drugs/Guidance ComplianceRegulatoryInformation/ Guidances/ucm072114.pdf. Accessed on 22 June 2009
38. Beal SL, Sheiner LB (1982) Estimating population kinetics. Crit Rev Biomed Eng 8(3):195-222
39. Ette EI, Williams PJ, Lane JR (2004) Population pharmacokinetics III: design, analysis, and application of population pharmacokinetic studies. Ann Pharmacother 38(12):2136-2144 (Pubitemid 40169387)
40. Wade JR, Beal SL, Sambol NC (1994) Interaction between structural, statistical, and covariate models in population pharmacokinetic analysis. J Pharmacokinet Biopharm 22(2):165-177 (Pubitemid 24288140)
41. Aarons L (1999) Software for population pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 36(4):255-264
42. Beal SL, Broeckman AJ (2006) NONMEM Users guides. Icon Development Solutions, Ellicott City, MD
43. Beal SL Broeckman AJ (1994) NONMEM Users Guide. V. University of California at San Francisco, San Francisco
44. Jelliffe RSA, Van Guilder M, et al. (1995) User manual for version 10.7 of the USC*PAC Collection of PC Programs, USC Laboratory of Applied Pharmacokinetics. USC School of Medicine, Los Angeles
45. Bustad A, Terziivanov D, Leary R et al (2006) Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies. Clin Pharmacokinet 45(4):365-383
46. Mentre F, Mallet A (1994) Handling covariates in population pharmacokinetics. Int J Biomed Comput 36(1-2):25-33 (Pubitemid 24173878)
47. Mandema JW, Verotta D, Sheiner LB (1992) Building population pharmacokinetic-pharmacodynamic models. I. Models for covariate effects. J Pharmacokinet Biopharm 20(5):511-528 (Pubitemid 23034413)
48. Anderson BJ, Holford NH (2008) Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol 48:303-332 (Pubitemid 351738156)
49. Anderson BJ, Allegaert K, Holford NH (2006) Population clinical pharmacology of children: general principles. Eur J Pediatr 165 (11):741-746 (Pubitemid 44440510)
50. Anderson BJ, Allegaert K, Holford NH (2006) Population clinical pharmacology of children: modelling covariate effects. Eur J Pediatr 165(12):819-829 (Pubitemid 44627767)
51. Meibohm B, Laer S, Panetta JC et al (2005) Population pharmacokinetic studies in pediatrics: issues in design and analysis. AAPS J 7(2):E475-E487 (Pubitemid 43071326)
52. Anderson BJ, Holford NH (2009) Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab Pharmacokinet 24(1):25-36
53. Engle WA (2004) Age terminology during the perinatal period. Pediatrics 114(5):1362-1364
54. Allegaert K, Anderson BJ, Cossey V et al (2006) Limited predictability of amikacin clearance in extreme premature neonates at birth. Br J Clin Pharmacol 61(1):39-48 (Pubitemid 43381236)
55. Knibbe CA, Krekels EH, van den Anker JN et al (2009) Morphine glucuronidation in preterm neonates, infants and children younger than 3 years. Clin Pharmacokinet 48(6):371-385
56. Mahmood I (2007) Prediction of drug clearance in children: impact of allometric exponents, body weight, and age. Ther Drug Monit 29(3):271-278
57. Mahmood I (2009) Application of fixed exponent 0.75 to the prediction of human drug clearance: an inaccurate and misleading concept. Drug Metabol Drug Interact 24(1):57-81
58. Sheiner LB, Ludden TM (1992) Population pharmacokinetics/ dynamics. Annu Rev Pharmacol Toxicol 32:185-209
59. Karlsson MO, Savic RM (2007) Diagnosing model diagnostics. Clin Pharmacol Ther 82(1):17-20 (Pubitemid 46944205)
60. Box G (1979) Robustness in the strategy of scientific model building. In: Launer RL, Wilkinson GN (eds) Robustness in statistics. Academic Press, New York, p 202
61. Brendel K, Dartois C, Comets E et al (2007) Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004. Clin Pharmacokinet 46(3):221-234
62. Ince I, de Wildt SN, Tibboel D et al (2009) Tailor-made drug treatment for children: creation of an infrastructure for data-sharing and population PK-PD modeling. Drug Discov Today 14 (5-6):316-320
63. Hooker AC, Staatz CE, Karlsson MO (2007) Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method. Pharm Res 24(12):2187-2197 (Pubitemid 350060706)
64. Fang L, Holford NH, Hinkle G et al (2007) Population pharmacokinetics of humanized monoclonal antibody HuCC49deltaCH2 and murine antibody CC49 in colorectal cancer patients. J Clin Pharmacol 47(2):227-237 (Pubitemid 46146489)
65. Brendel K, Comets E, Laffont C et al (2006) Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide. Pharm Res 23(9):2036-2049
66. Comets E, Brendel K, Mentre F (2008) Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R. Comput Methods Programs Biomed 90(2):154-166
67. Foracchia M, Hooker A, Vicini P et al (2004) POPED, a software for optimal experiment design in population kinetics. Comput Methods Programs Biomed 74(1):29-46 (Pubitemid 38283678)
68. Duffull SB, Eccleston J, Kimco H (2008) WinPOPT user guide Version 1.2. School of Pharmacy, University of Otago, Otago, New Zealand
69. Retout S, Mentre F (2003) Optimization of individual and population designs using Splus. J Pharmacokinet Pharmacodyn 30(6):417-443 (Pubitemid 38221933)
70. Duffull SB (2001) Design of clinical pharmacology trials. Clin Exp Pharmacol Physiol 28(11):905-912
71. Knibbe CA, Melenhorst-de Jong G, Mestrom M et al (2002) Pharmacokinetics and effects of propofol 6% for short-term sedation in paediatric patients following cardiac surgery. Br J Clin Pharmacol 54(4):415-422 (Pubitemid 35334955)
72. Breimer DD (2008) PK/PD modelling and beyond: impact on drug development. Pharm Res 25(12):2720-2722
73. Alcorn J, McNamara PJ (2008) Using ontogeny information to build predictive models for drug elimination. Drug Discov Today 13(11-12):507-512
74. Johnson TN (2005) Modelling approaches to dose estimation in children. Br J Clin Pharmacol 59(6):663-669